董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | 男 | Director | 46 | 11.93万美元 | 未持股 | 2025-12-31 |
| Steven Stein | 男 | Director | 58 | 未披露 | 未持股 | 2025-12-31 |
| Thomas Civik | 男 | Chair of the Board | 56 | 未披露 | 未持股 | 2025-12-31 |
| Steve Forte | 男 | President,Chief Executive Officer,Chief Financial Officer and Director | 46 | 未披露 | 未持股 | 2025-12-31 |
| Carol A. Schafer | 女 | Director | 61 | 11.38万美元 | 未持股 | 2025-12-31 |
| Ann D. Rhoads | 女 | Director | 60 | 未披露 | 未持股 | 2025-12-31 |
| David Bonita | 男 | Director | 50 | 未披露 | 未持股 | 2025-12-31 |
| Susan M. Molineaux | 女 | Director | 71 | 未披露 | 未持股 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steve Forte | 男 | President,Chief Executive Officer,Chief Financial Officer and Director | 46 | 未披露 | 未持股 | 2025-12-31 |
| Sandra Alves | 女 | Senior Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- Samarth Kulkarni
-
Samarth Kulkarni，他于2021年2月加入Centessa Pharmaceuticals Plc董事会。Kulkarni博士自2017年12月1日起担任CRISPR Therapeutics AG（纳斯达克股票代码：CRSP）的首席执行官，自2018年6月起担任其董事会成员。在此之前，Kulkarni博士从2017年5月到2017年11月30日担任CRISPR Therapeutics AG的总裁兼首席商务官，在此之前，从2015年8月起担任其首席商务官。加入CRISPR Therapeutics AG之前，Kulkarni博士从2006年到2015年7月在McKinsey & Company担任多个职位，最近担任制药和生物技术实践的合伙人。Kulkarni博士自2019年12月起担任肿瘤学公司Black Diamond Therapeutics, Inc.的董事会成员。他持有the University of Washington的生物工程和纳米技术博士学位，以及the Indian Institute of Technology的学士学位。Kulkarni博士在领先的科学和商业期刊上发表了多篇文章。
Samarth Kulkarni,joined board of directors in February 2021. Dr. Kulkarni has served as Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP) since December 1, 2017 and as a member of its Board of Directors since June 2018. Previous to that, Dr. Kulkarni served as President and Chief Business Officer of CRISPR Therapeutics AG from May 2017 to November 30, 2017 and, before that, as its Chief Business Officer from August 2015. Prior to joining CRISPR Therapeutics AG, Dr. Kulkarni was at McKinsey & Company from 2006 to July 2015, with various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr. Kulkarni has also served as a member of the board of directors of Black Diamond Therapeutics and Repare Therapeutics since 2019. Dr. Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. Dr. Kulkarni has authored several publications in leading scientific and business journals. - Samarth Kulkarni，他于2021年2月加入Centessa Pharmaceuticals Plc董事会。Kulkarni博士自2017年12月1日起担任CRISPR Therapeutics AG（纳斯达克股票代码：CRSP）的首席执行官，自2018年6月起担任其董事会成员。在此之前，Kulkarni博士从2017年5月到2017年11月30日担任CRISPR Therapeutics AG的总裁兼首席商务官，在此之前，从2015年8月起担任其首席商务官。加入CRISPR Therapeutics AG之前，Kulkarni博士从2006年到2015年7月在McKinsey & Company担任多个职位，最近担任制药和生物技术实践的合伙人。Kulkarni博士自2019年12月起担任肿瘤学公司Black Diamond Therapeutics, Inc.的董事会成员。他持有the University of Washington的生物工程和纳米技术博士学位，以及the Indian Institute of Technology的学士学位。Kulkarni博士在领先的科学和商业期刊上发表了多篇文章。
- Samarth Kulkarni,joined board of directors in February 2021. Dr. Kulkarni has served as Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP) since December 1, 2017 and as a member of its Board of Directors since June 2018. Previous to that, Dr. Kulkarni served as President and Chief Business Officer of CRISPR Therapeutics AG from May 2017 to November 30, 2017 and, before that, as its Chief Business Officer from August 2015. Prior to joining CRISPR Therapeutics AG, Dr. Kulkarni was at McKinsey & Company from 2006 to July 2015, with various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr. Kulkarni has also served as a member of the board of directors of Black Diamond Therapeutics and Repare Therapeutics since 2019. Dr. Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. Dr. Kulkarni has authored several publications in leading scientific and business journals.
- Steven Stein
-
Steven Stein，自2016年5月起担任执行副总裁兼首席医疗官，并于2015年3月加入Incyte担任高级副总裁兼首席医疗官。在加入Incyte之前，从2011年5月到2015年2月，他担任Novartis Pharmaceuticals的美国临床开发和医疗事务高级副总裁。从2004年2月到2011年4月，Stein博士担任GlaxoSmithKline的全球肿瘤学、临床开发副总裁和血液学和支持性护理药物开发主管。他于1998年至2001年在宾夕法尼亚大学担任血液学/肿瘤学博士后，并于1990年在南非约翰内斯堡的Witwatersrand大学获得医学博士学位。
Steven Stein,has served as Executive Vice President and Chief Medical Officer since May 2016 and joined Incyte as Senior Vice President and Chief Medical Officer in March 2015. Prior to joining Incyte, from May 2011 to February 2015, he was the Senior Vice President, U.S. Clinical Development & Medical Affairs at Novartis Pharmaceuticals. From February 2004 to April 2011, Dr. Stein was the Vice President, Global Oncology, Clinical Development and the Head of Medicines Development for Hematology and Supportive Care for GlaxoSmithKline. Dr. Stein held a post-doctoral fellowship in hematology/oncology at the University of Pennsylvania from 1998 to 2001, and earned his M.D. from the University of Witwatersrand in Johannesburg, South Africa, in 1990. - Steven Stein，自2016年5月起担任执行副总裁兼首席医疗官，并于2015年3月加入Incyte担任高级副总裁兼首席医疗官。在加入Incyte之前，从2011年5月到2015年2月，他担任Novartis Pharmaceuticals的美国临床开发和医疗事务高级副总裁。从2004年2月到2011年4月，Stein博士担任GlaxoSmithKline的全球肿瘤学、临床开发副总裁和血液学和支持性护理药物开发主管。他于1998年至2001年在宾夕法尼亚大学担任血液学/肿瘤学博士后，并于1990年在南非约翰内斯堡的Witwatersrand大学获得医学博士学位。
- Steven Stein,has served as Executive Vice President and Chief Medical Officer since May 2016 and joined Incyte as Senior Vice President and Chief Medical Officer in March 2015. Prior to joining Incyte, from May 2011 to February 2015, he was the Senior Vice President, U.S. Clinical Development & Medical Affairs at Novartis Pharmaceuticals. From February 2004 to April 2011, Dr. Stein was the Vice President, Global Oncology, Clinical Development and the Head of Medicines Development for Hematology and Supportive Care for GlaxoSmithKline. Dr. Stein held a post-doctoral fellowship in hematology/oncology at the University of Pennsylvania from 1998 to 2001, and earned his M.D. from the University of Witwatersrand in Johannesburg, South Africa, in 1990.
- Thomas Civik
-
Thomas Civik于2017年11月加入Foundation Medicine，担任公司首席商务官。Civik先生于1999年至2017年在Genentech&8217；s Commercial Organization工作，最近担任销售与市场营销的Vice President，在那里Civik先生负责领导多个领先肿瘤产品的商业化工作。在加入Genentech肿瘤团队之前，Civik先生领导了专注于中风和心血管疾病的产品组合的商业活动。Civik先生在Genentech的管理式护理领域开始了他的职业生涯，担任越来越复杂的角色，专注于为整个Genentech投资组合提供访问权限。任职Genentech公司之前，他曾任职Sanofi公司8年，在那里他曾担任销售、销售管理和账户管理职务，在那里他曾担任日益复杂的职务。Civik先生在圣诺伯特学院（Saint Norbert College）获得学士学位，并在西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University）获得工商管理硕士学位。
Thomas Civik has served as a member of board of directors since September 2021. Since April 2020 he has served as President, Chief Executive Officer and a member of the board of directors at Five Prime Therapeutics, Inc. From November 2017 until September 2019 Mr. Civik served as Chief Commercial Officer of Foundation Medicine, Inc., a genomic profiling and molecular information company. From July 1992 to December 2000 he served at Sanofi S.A. in sales and marketing roles of increasing responsibility. Mr. Civik received an M.B.A. in business strategy and marketing from the Kellogg School of Management at Northwestern University and a B.A. in political science from Saint Norbert College. - Thomas Civik于2017年11月加入Foundation Medicine，担任公司首席商务官。Civik先生于1999年至2017年在Genentech&8217；s Commercial Organization工作，最近担任销售与市场营销的Vice President，在那里Civik先生负责领导多个领先肿瘤产品的商业化工作。在加入Genentech肿瘤团队之前，Civik先生领导了专注于中风和心血管疾病的产品组合的商业活动。Civik先生在Genentech的管理式护理领域开始了他的职业生涯，担任越来越复杂的角色，专注于为整个Genentech投资组合提供访问权限。任职Genentech公司之前，他曾任职Sanofi公司8年，在那里他曾担任销售、销售管理和账户管理职务，在那里他曾担任日益复杂的职务。Civik先生在圣诺伯特学院（Saint Norbert College）获得学士学位，并在西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University）获得工商管理硕士学位。
- Thomas Civik has served as a member of board of directors since September 2021. Since April 2020 he has served as President, Chief Executive Officer and a member of the board of directors at Five Prime Therapeutics, Inc. From November 2017 until September 2019 Mr. Civik served as Chief Commercial Officer of Foundation Medicine, Inc., a genomic profiling and molecular information company. From July 1992 to December 2000 he served at Sanofi S.A. in sales and marketing roles of increasing responsibility. Mr. Civik received an M.B.A. in business strategy and marketing from the Kellogg School of Management at Northwestern University and a B.A. in political science from Saint Norbert College.
- Steve Forte
-
Steve Forte自2019年10月起担任首席财务官执行Vice President。在加入我们之前，他曾于2018年8月至2019年6月担任Clementia PharmaceuticalsInc.首席财务官，在此期间，Clementia被Ipsen S.A.收购，2015年9月至2018年8月，福特担任Thinking Capital Financial Corporation首席财务官，他是一家加拿大金融技术公司，在那里他最终领导公司通过出售目的投资。从2014年9月到2015年9月，他曾担任CST Canada Co.的财务执行董事。从2005年到2014年，Forte先生在Aptalis Pharma Inc.担任越来越重要的职务，包括最近担任财务报告Vice President，负责该公司的整体公司控制职能。他目前任职于Profound MedicalCorp.董事会，在那里他也是审计委员会的成员。Forte先生在康科迪亚大学（Concordia University）获得会计学商业学士学位，是魁北克省（Qu&233；BEC）的一名注册专业会计师，也是一名不在ISACA执业的注册信息系统审计师。
Steve Forte has served as our Executive Vice President, Chief Financial Officer since October 2019. Prior to joining us, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc. from August 2018 through June 2019 during which time Clementia was acquired by Ipsen S.A. From September 2015 to August 2018 Mr. Forte served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments. From September 2014 to September 2015 he served as Executive Director of Finance of CST Canada Co. From 2005 to 2014 Mr. Forte held positions of increasing responsibility at Aptalis Pharma Inc., including most recently holding the position of Vice President, Financial Reporting where he was responsible for the overall corporate controllership function of the company. He currently serves on the board of directors of Profound Medical Corp., where he is also a member of the audit committee. Mr. Forte received his Bachelor of Commerce in accountancy from Concordia University and is a Certified Professional Accountant in the Province of Québec and a Certified Information Systems Auditor non-practicing with ISACA. - Steve Forte自2019年10月起担任首席财务官执行Vice President。在加入我们之前，他曾于2018年8月至2019年6月担任Clementia PharmaceuticalsInc.首席财务官，在此期间，Clementia被Ipsen S.A.收购，2015年9月至2018年8月，福特担任Thinking Capital Financial Corporation首席财务官，他是一家加拿大金融技术公司，在那里他最终领导公司通过出售目的投资。从2014年9月到2015年9月，他曾担任CST Canada Co.的财务执行董事。从2005年到2014年，Forte先生在Aptalis Pharma Inc.担任越来越重要的职务，包括最近担任财务报告Vice President，负责该公司的整体公司控制职能。他目前任职于Profound MedicalCorp.董事会，在那里他也是审计委员会的成员。Forte先生在康科迪亚大学（Concordia University）获得会计学商业学士学位，是魁北克省（Qu&233；BEC）的一名注册专业会计师，也是一名不在ISACA执业的注册信息系统审计师。
- Steve Forte has served as our Executive Vice President, Chief Financial Officer since October 2019. Prior to joining us, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc. from August 2018 through June 2019 during which time Clementia was acquired by Ipsen S.A. From September 2015 to August 2018 Mr. Forte served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments. From September 2014 to September 2015 he served as Executive Director of Finance of CST Canada Co. From 2005 to 2014 Mr. Forte held positions of increasing responsibility at Aptalis Pharma Inc., including most recently holding the position of Vice President, Financial Reporting where he was responsible for the overall corporate controllership function of the company. He currently serves on the board of directors of Profound Medical Corp., where he is also a member of the audit committee. Mr. Forte received his Bachelor of Commerce in accountancy from Concordia University and is a Certified Professional Accountant in the Province of Québec and a Certified Information Systems Auditor non-practicing with ISACA.
- Carol A. Schafer
-
CarolA.Schafer自2019年5月起担任上市公司Five PrimeTherapeutics，Inc.的董事会成员，并担任审计委员会以及提名和公司治理委员会成员。此外，Schafer女士自2019年3月起担任私营生物技术公司Repare Therapeutics，Inc.的董事会和审计委员会成员，并担任非营利实体OneGoal NY的非信托董事会成员。她目前也担任Hyphen Advisors公司（公司为上市和私人公司和董事会提供咨询、咨询和董事会服务，涉及融资战略和执行、财务规划和分析、投资者访问和消息传递）的管理合伙人，以及战略计划。Schafer女士在投资银行和股权资本市场以及生物制药部门的公司融资和业务发展方面拥有超过25年的经验，在为公共和私营梦百合公司提供融资和便利投资者进入方面拥有丰富的经验。Schafer女士最近担任富国证券（Wells Fargo Securities）股票资本市场副主席。任职Wells Fargo公司之前，Schafer女士曾担任Lexicon Pharmaceuticals公司的财务和业务发展Vice President。职业生涯早期，Schafer女士曾担任J.P.Morgan的股票资本市场部门主管，担任董事总经理。Schafer女士在波士顿学院（Boston College）获得文学学士学位，并在纽约大学（New York University）获得工商管理硕士学位。
Carol A. Schafer has served on the board of directors of Five Prime Therapeutics, Inc., a publicly traded company, since May 2019 where she serves on the audit committee and nominating and corporate governance committee. Additionally, Ms. Schafer has served on the board of directors and audit committee of Repare Therapeutics, Inc., a private biotechnology company, and as a non-fiduciary board member of OneGoal NY, a non-profit entity, since March 2019. She also currently serves as managing partner at Hyphen Advisors, LLC, a firm that provides advisory, consulting and board services to public and private companies and boards of directors on topics such as financing strategy and execution, financial planning and analysis, investor access and messaging, and strategic initiatives. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets, as well as in corporate finance and business development in the biopharmaceutical sector, with substantial experience financing and facilitating investor access for public and private healthcare companies. Ms. Schafer most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities. Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals. Earlier in her career, Ms. Schafer served as an Equity Capital Markets Sector Head in her role as Managing Director at J.P. Morgan. Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University. - CarolA.Schafer自2019年5月起担任上市公司Five PrimeTherapeutics，Inc.的董事会成员，并担任审计委员会以及提名和公司治理委员会成员。此外，Schafer女士自2019年3月起担任私营生物技术公司Repare Therapeutics，Inc.的董事会和审计委员会成员，并担任非营利实体OneGoal NY的非信托董事会成员。她目前也担任Hyphen Advisors公司（公司为上市和私人公司和董事会提供咨询、咨询和董事会服务，涉及融资战略和执行、财务规划和分析、投资者访问和消息传递）的管理合伙人，以及战略计划。Schafer女士在投资银行和股权资本市场以及生物制药部门的公司融资和业务发展方面拥有超过25年的经验，在为公共和私营梦百合公司提供融资和便利投资者进入方面拥有丰富的经验。Schafer女士最近担任富国证券（Wells Fargo Securities）股票资本市场副主席。任职Wells Fargo公司之前，Schafer女士曾担任Lexicon Pharmaceuticals公司的财务和业务发展Vice President。职业生涯早期，Schafer女士曾担任J.P.Morgan的股票资本市场部门主管，担任董事总经理。Schafer女士在波士顿学院（Boston College）获得文学学士学位，并在纽约大学（New York University）获得工商管理硕士学位。
- Carol A. Schafer has served on the board of directors of Five Prime Therapeutics, Inc., a publicly traded company, since May 2019 where she serves on the audit committee and nominating and corporate governance committee. Additionally, Ms. Schafer has served on the board of directors and audit committee of Repare Therapeutics, Inc., a private biotechnology company, and as a non-fiduciary board member of OneGoal NY, a non-profit entity, since March 2019. She also currently serves as managing partner at Hyphen Advisors, LLC, a firm that provides advisory, consulting and board services to public and private companies and boards of directors on topics such as financing strategy and execution, financial planning and analysis, investor access and messaging, and strategic initiatives. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets, as well as in corporate finance and business development in the biopharmaceutical sector, with substantial experience financing and facilitating investor access for public and private healthcare companies. Ms. Schafer most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities. Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals. Earlier in her career, Ms. Schafer served as an Equity Capital Markets Sector Head in her role as Managing Director at J.P. Morgan. Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University.
- Ann D. Rhoads
-
Ann D. Rhoads， 自2010年3月起担任执行副总裁、首席财务官和风险官、以及秘书的职位。2000年到2009年12月担任Premier, Inc.（一家医疗保健服务公司）首席财务官，负责金融管理、战略规划、业务开发、信息技术和道德与合规的所有事项。1998年8月到2000年担任Premier战略活动副总裁，负责监管战略投资，包括风险资本基金以及协助Premier的运营部门提供长期战略规划。加入Premier之前，她在Sprout Group（Donaldson, Lufkin & Jenrette的风险资本附属公司，现在是Credit Suisse First Boston, Bain & Company 和 Merrill Lynch Capital Partners的一部份。 Merrill Lynch Capital Partners现名为Stonington Partners） 担任多个职位。她现在是 Globus Medical Inc.和 Evoke Pharma, Inc.董事。她持有Arkansas大学理学学士学位和哈佛商学院（the Harvard Business School。）工商管理硕士学位。
Ann D. Rhoads,most recently served as Chief Financial Officer of Forty Seven, Inc., a publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was Executive Vice President and Chief Financial Officer of Zogenix, Inc., a publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Graduate School of Business Administration. - Ann D. Rhoads， 自2010年3月起担任执行副总裁、首席财务官和风险官、以及秘书的职位。2000年到2009年12月担任Premier, Inc.（一家医疗保健服务公司）首席财务官，负责金融管理、战略规划、业务开发、信息技术和道德与合规的所有事项。1998年8月到2000年担任Premier战略活动副总裁，负责监管战略投资，包括风险资本基金以及协助Premier的运营部门提供长期战略规划。加入Premier之前，她在Sprout Group（Donaldson, Lufkin & Jenrette的风险资本附属公司，现在是Credit Suisse First Boston, Bain & Company 和 Merrill Lynch Capital Partners的一部份。 Merrill Lynch Capital Partners现名为Stonington Partners） 担任多个职位。她现在是 Globus Medical Inc.和 Evoke Pharma, Inc.董事。她持有Arkansas大学理学学士学位和哈佛商学院（the Harvard Business School。）工商管理硕士学位。
- Ann D. Rhoads,most recently served as Chief Financial Officer of Forty Seven, Inc., a publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was Executive Vice President and Chief Financial Officer of Zogenix, Inc., a publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Graduate School of Business Administration.
- David Bonita
-
David Bonita，2004年6月至2013年6月，Bonita博士在OrbiMed担任其他职务。Bonita博士自2014年1月起担任上市制药公司Tricida, Inc.的董事会成员，自2016年3月起担任心律失常管理公司Acutus Medical Medical Inc，自2016年3月起担任上市肿瘤学公司Ikena Oncology, Inc.，自2016年3月起担任上市肿瘤学公司Prelude Therapeutics，Inc.自2016年7月起担任上市肿瘤学公司，自2019年9月起担任专注于上市癌症的生物技术公司Repare Therapeutics Inc.的董事会成员。Bonita博士此前还曾于2013年4月至2019年4月在上市制药公司Clementia Pharmaceuticals Inc.的董事会任职，此前曾于2013年10月至2017年12月在上市生物制药公司Loxo Oncology, Inc.、2014年4月至2019年6月在上市医疗器械公司SI-BONE, Inc.以及于2008年1月至2018年6月在上市医疗器械公司ViewRay Inc.任职。Bonita博士目前在多家私营公司的董事会任职，此前也曾任职。Bonita博士此前还曾在摩根士丹利和瑞银的医疗保健投资银行集团担任公司融资分析师。他在哈佛医学院进行的基于信号转导研究的同行评审期刊上发表了科学文章。他在哈佛大学获得生物学学士学位，并在哥伦比亚大学获得联合医学博士/工商管理硕士学位。
David Bonita,has served as a member of Board since June 2016. Dr. Bonita is a member at OrbiMed Advisors LLC, an investment firm. Dr. Bonita currently serves on the boards of directors of Acutus Medical, Inc., Ikena Oncology, Inc., Repare Therapeutics Inc., and Third Harmonic Bio, Inc., as well as several private companies. Dr. Bonita also previously served on the boards of directors of IMARA Inc. and Tricida, Inc. Prior to OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He received a B.A. in Biology from Harvard University and a joint M.D./M.B.A. from Columbia University. - David Bonita，2004年6月至2013年6月，Bonita博士在OrbiMed担任其他职务。Bonita博士自2014年1月起担任上市制药公司Tricida, Inc.的董事会成员，自2016年3月起担任心律失常管理公司Acutus Medical Medical Inc，自2016年3月起担任上市肿瘤学公司Ikena Oncology, Inc.，自2016年3月起担任上市肿瘤学公司Prelude Therapeutics，Inc.自2016年7月起担任上市肿瘤学公司，自2019年9月起担任专注于上市癌症的生物技术公司Repare Therapeutics Inc.的董事会成员。Bonita博士此前还曾于2013年4月至2019年4月在上市制药公司Clementia Pharmaceuticals Inc.的董事会任职，此前曾于2013年10月至2017年12月在上市生物制药公司Loxo Oncology, Inc.、2014年4月至2019年6月在上市医疗器械公司SI-BONE, Inc.以及于2008年1月至2018年6月在上市医疗器械公司ViewRay Inc.任职。Bonita博士目前在多家私营公司的董事会任职，此前也曾任职。Bonita博士此前还曾在摩根士丹利和瑞银的医疗保健投资银行集团担任公司融资分析师。他在哈佛医学院进行的基于信号转导研究的同行评审期刊上发表了科学文章。他在哈佛大学获得生物学学士学位，并在哥伦比亚大学获得联合医学博士/工商管理硕士学位。
- David Bonita,has served as a member of Board since June 2016. Dr. Bonita is a member at OrbiMed Advisors LLC, an investment firm. Dr. Bonita currently serves on the boards of directors of Acutus Medical, Inc., Ikena Oncology, Inc., Repare Therapeutics Inc., and Third Harmonic Bio, Inc., as well as several private companies. Dr. Bonita also previously served on the boards of directors of IMARA Inc. and Tricida, Inc. Prior to OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He received a B.A. in Biology from Harvard University and a joint M.D./M.B.A. from Columbia University.
- Susan M. Molineaux
-
Susan M. Molineaux，2012年9月以来担任Geron董事。Calithera Biosciences是一家开发肿瘤治疗的私营生物技术公司，自从2010年6月联合建立这家公司以来，她担任公司的首席执行官兼总裁。在Calithera之前，Molineaux博士联合创立一家肿瘤为主导方向的生物制药公司Proteolix，并且2003年12月到2005年12月担任以及2009年2月到2009年11月担任首席科学官，2006年1月到2009年2月担任总裁兼首席执行官。Molineaux博士负责Proteolix第二代蛋白酶体抑制剂carfilzomib，现在市场上称为Kyprolis的开发，治疗多发性骨髓瘤，负责从发现到临床试验完成，加速获得批准，直到公司2009年11月被一家全球以肿瘤为主导方向的生物制药公司Onyx Pharmaceuticals收购。2000年到2003年，Molineaux博士担任一家专注炎症和自身免疫性疾病的生物制药公司Rigel Pharmaceuticals的生物副总裁。1999年到2000年以及1994年到1999年，她在一家肿瘤学为主导的生物制药公司Praecis Pharmaceuticals担任生物副总裁。1989年到1994年，她是一家制药公司默克的免疫学组的科学家。Molineaux博士拥有史密斯学院的生物学学士学位和约翰霍普金斯大学分子生物学的博士学位，也完成了哥伦比亚大学的博士后。她目前担任北加利福尼亚生命科学协会Bay Bio的主席，旧金山海岸数学科学研究项目We Teach Science董事会成员。
Susan M. Molineaux, Ph.D. has served as a director since April 2015. Dr. Molineaux has served as President, Chief Executive Officer and as a member of the board of directors of Calithera Biosciences, Inc. since she co-founded the biopharmaceutical company in March 2010. Dr. Molineaux co-founded Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005 Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolix's acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003 Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From 1999 to 2000 she served as Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and from 1994 through 1999 she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1994 she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux also serves as a member of the board of directors of Geron Corporation, a biopharmaceutical company and served as a member of the board of directors of the California Life Sciences Association until March 2016. In June 2017 Dr. Molineaux joined the board of trustees of Smith College and she also serves as on the board of directors of Cyteir Therapeutics, Inc., a privately held biotechnology company. She is also a Scientific Advisor at Lightstone Ventures. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and she completed a postdoctoral fellowship at Columbia University. - Susan M. Molineaux，2012年9月以来担任Geron董事。Calithera Biosciences是一家开发肿瘤治疗的私营生物技术公司，自从2010年6月联合建立这家公司以来，她担任公司的首席执行官兼总裁。在Calithera之前，Molineaux博士联合创立一家肿瘤为主导方向的生物制药公司Proteolix，并且2003年12月到2005年12月担任以及2009年2月到2009年11月担任首席科学官，2006年1月到2009年2月担任总裁兼首席执行官。Molineaux博士负责Proteolix第二代蛋白酶体抑制剂carfilzomib，现在市场上称为Kyprolis的开发，治疗多发性骨髓瘤，负责从发现到临床试验完成，加速获得批准，直到公司2009年11月被一家全球以肿瘤为主导方向的生物制药公司Onyx Pharmaceuticals收购。2000年到2003年，Molineaux博士担任一家专注炎症和自身免疫性疾病的生物制药公司Rigel Pharmaceuticals的生物副总裁。1999年到2000年以及1994年到1999年，她在一家肿瘤学为主导的生物制药公司Praecis Pharmaceuticals担任生物副总裁。1989年到1994年，她是一家制药公司默克的免疫学组的科学家。Molineaux博士拥有史密斯学院的生物学学士学位和约翰霍普金斯大学分子生物学的博士学位，也完成了哥伦比亚大学的博士后。她目前担任北加利福尼亚生命科学协会Bay Bio的主席，旧金山海岸数学科学研究项目We Teach Science董事会成员。
- Susan M. Molineaux, Ph.D. has served as a director since April 2015. Dr. Molineaux has served as President, Chief Executive Officer and as a member of the board of directors of Calithera Biosciences, Inc. since she co-founded the biopharmaceutical company in March 2010. Dr. Molineaux co-founded Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005 Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolix's acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003 Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From 1999 to 2000 she served as Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and from 1994 through 1999 she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1994 she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux also serves as a member of the board of directors of Geron Corporation, a biopharmaceutical company and served as a member of the board of directors of the California Life Sciences Association until March 2016. In June 2017 Dr. Molineaux joined the board of trustees of Smith College and she also serves as on the board of directors of Cyteir Therapeutics, Inc., a privately held biotechnology company. She is also a Scientific Advisor at Lightstone Ventures. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and she completed a postdoctoral fellowship at Columbia University.
高管简历
中英对照 | 中文 | 英文- Steve Forte
Steve Forte自2019年10月起担任首席财务官执行Vice President。在加入我们之前，他曾于2018年8月至2019年6月担任Clementia PharmaceuticalsInc.首席财务官，在此期间，Clementia被Ipsen S.A.收购，2015年9月至2018年8月，福特担任Thinking Capital Financial Corporation首席财务官，他是一家加拿大金融技术公司，在那里他最终领导公司通过出售目的投资。从2014年9月到2015年9月，他曾担任CST Canada Co.的财务执行董事。从2005年到2014年，Forte先生在Aptalis Pharma Inc.担任越来越重要的职务，包括最近担任财务报告Vice President，负责该公司的整体公司控制职能。他目前任职于Profound MedicalCorp.董事会，在那里他也是审计委员会的成员。Forte先生在康科迪亚大学（Concordia University）获得会计学商业学士学位，是魁北克省（Qu&233；BEC）的一名注册专业会计师，也是一名不在ISACA执业的注册信息系统审计师。
Steve Forte has served as our Executive Vice President, Chief Financial Officer since October 2019. Prior to joining us, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc. from August 2018 through June 2019 during which time Clementia was acquired by Ipsen S.A. From September 2015 to August 2018 Mr. Forte served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments. From September 2014 to September 2015 he served as Executive Director of Finance of CST Canada Co. From 2005 to 2014 Mr. Forte held positions of increasing responsibility at Aptalis Pharma Inc., including most recently holding the position of Vice President, Financial Reporting where he was responsible for the overall corporate controllership function of the company. He currently serves on the board of directors of Profound Medical Corp., where he is also a member of the audit committee. Mr. Forte received his Bachelor of Commerce in accountancy from Concordia University and is a Certified Professional Accountant in the Province of Québec and a Certified Information Systems Auditor non-practicing with ISACA.- Steve Forte自2019年10月起担任首席财务官执行Vice President。在加入我们之前，他曾于2018年8月至2019年6月担任Clementia PharmaceuticalsInc.首席财务官，在此期间，Clementia被Ipsen S.A.收购，2015年9月至2018年8月，福特担任Thinking Capital Financial Corporation首席财务官，他是一家加拿大金融技术公司，在那里他最终领导公司通过出售目的投资。从2014年9月到2015年9月，他曾担任CST Canada Co.的财务执行董事。从2005年到2014年，Forte先生在Aptalis Pharma Inc.担任越来越重要的职务，包括最近担任财务报告Vice President，负责该公司的整体公司控制职能。他目前任职于Profound MedicalCorp.董事会，在那里他也是审计委员会的成员。Forte先生在康科迪亚大学（Concordia University）获得会计学商业学士学位，是魁北克省（Qu&233；BEC）的一名注册专业会计师，也是一名不在ISACA执业的注册信息系统审计师。
- Steve Forte has served as our Executive Vice President, Chief Financial Officer since October 2019. Prior to joining us, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc. from August 2018 through June 2019 during which time Clementia was acquired by Ipsen S.A. From September 2015 to August 2018 Mr. Forte served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments. From September 2014 to September 2015 he served as Executive Director of Finance of CST Canada Co. From 2005 to 2014 Mr. Forte held positions of increasing responsibility at Aptalis Pharma Inc., including most recently holding the position of Vice President, Financial Reporting where he was responsible for the overall corporate controllership function of the company. He currently serves on the board of directors of Profound Medical Corp., where he is also a member of the audit committee. Mr. Forte received his Bachelor of Commerce in accountancy from Concordia University and is a Certified Professional Accountant in the Province of Québec and a Certified Information Systems Auditor non-practicing with ISACA.
- Sandra Alves
Sandra Alves，自2025年4月起担任Repare Therapeutics Inc.高级副总裁、首席会计官，此前于2020年3月至2025年4月担任Repare Therapeutics Inc.副总裁、财务及公司控制人。在加入Repare Therapeutics Inc.之前，Alves女士在Clementia Pharmaceuticals Inc.担任控制人，2013年5月至2020年1月，期间Clementia被Ipsen S.A.收购。2007年6月至2013年4月，Alves女士在Thallion Pharmaceuticals Inc.担任控制人，直至其被Bellus Health收购。Alves女士拥有康考迪亚大学会计学学士学位，是一名注册会计师。
Sandra Alves,has served as Repare Therapeutics Inc. Senior Vice President, Chief Accounting Officer since April 2025, and previously served as Repare Therapeutics Inc. Vice President, Finance and Corporate Controller from March 2020 to April 2025. Prior to joining Repare Therapeutics Inc. , Ms. Alves served as controller at Clementia Pharmaceuticals Inc., from May 2013 to January 2020, during which time Clementia was acquired by Ipsen S.A. From June 2007 to April 2013, Ms. Alves served as controller at Thallion Pharmaceuticals Inc. until its acquisition by Bellus Health. Ms. Alves holds a B.Com. in accounting from Concordia University and is a Certified Public Accountant.- Sandra Alves，自2025年4月起担任Repare Therapeutics Inc.高级副总裁、首席会计官，此前于2020年3月至2025年4月担任Repare Therapeutics Inc.副总裁、财务及公司控制人。在加入Repare Therapeutics Inc.之前，Alves女士在Clementia Pharmaceuticals Inc.担任控制人，2013年5月至2020年1月，期间Clementia被Ipsen S.A.收购。2007年6月至2013年4月，Alves女士在Thallion Pharmaceuticals Inc.担任控制人，直至其被Bellus Health收购。Alves女士拥有康考迪亚大学会计学学士学位，是一名注册会计师。
- Sandra Alves,has served as Repare Therapeutics Inc. Senior Vice President, Chief Accounting Officer since April 2025, and previously served as Repare Therapeutics Inc. Vice President, Finance and Corporate Controller from March 2020 to April 2025. Prior to joining Repare Therapeutics Inc. , Ms. Alves served as controller at Clementia Pharmaceuticals Inc., from May 2013 to January 2020, during which time Clementia was acquired by Ipsen S.A. From June 2007 to April 2013, Ms. Alves served as controller at Thallion Pharmaceuticals Inc. until its acquisition by Bellus Health. Ms. Alves holds a B.Com. in accounting from Concordia University and is a Certified Public Accountant.